Preclinical biotechs taking larger chunk of venture funding
The percent of venture rounds raised by preclinical biotech has grown over the last five years
Preclinical biotechs are increasingly taking in more venture than their clinical counterparts, including later-stage rounds such as series C, according to an analysis of financings in BioCentury’s BCIQ database.
In 2018, the 196 venture rounds raised by preclinical biotechs accounted for 58% of all biotech venture financings. Last year, that fraction rose to 66%, with 269 financings raised by preclinical companies...